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Summary 
We reported that interleukin  (IL) 6 alone cannot induce osteoclast formation in cocultures of 
mouse bone marrow and osteoblastic cells,  but soluble IL-6 receptor (IL-6R) strikingly trig- 
gered osteoclast formation induced by IL-6. In this study, we examined the mechanism of os- 
teoclast formation by IL-6 and related cytokines through the interaction between osteoblastic 
cells and osteoclast progenitors. When dexamethasone was added to the cocultures, IL-6 could 
stimulate osteoclast formation without the help of soluble IL-6K. Osteoblastic cells expressed a 
very low level of IL-6R mRNA, whereas fresh mouse spleen and bone marrow cells,  both of 
which are considered to be osteoclast progenitors, constitutively expressed relatively high levels 
of IL-6K mRNA. Treatment of osteoblastic cells with dexamethasone induced a marked in- 
crease in the expression of IL-6R mRNA. By immunoblotting with antiphosphotyrosine anti- 
body, IL-6 did not tyrosine-phosphorylate a protein with a molecular mass of 130 kD in osteo- 
blastic cells  but did so in dexamethasone-pretreated osteoblastic cells.  Osteoblastic cells  from 
transgenic mice constitutively expressing human IL-6K could support osteoclast development 
in the presence of human IL-6 alone in cocultures with normal spleen cells.  In contrast, osteo- 
clast progenitors in spleen cells from transgenic mice overexpressing human IL-6P,. were not 
able to differentiate into osteoclasts in response to IL-6 in cocultures with normal osteoblastic 
cells.  These results clearly indicate that the abihty of IL-6 to induce osteoclast differentiation 
depends on signal transduction mediated by IL-6R expressed on osteoblastic cells but not on 
osteoclast progenitors. 
B 
one formation and resorption are coupled through the 
actions of several locally produced growth factors and 
cytokines.  Osteoblastic  cells  have  receptors  for  bone- 
resorbing hormones, including parathyroid hormone, PGs, 
and  10t,25-dihydroxyvitamin D 3 [10t,25(OH)2D3] 1.  How- 
ever, there is no convincing evidence of direct responses to 
these  bone-resorbing hormones in  osteoclast lineage  cells 
A portion of this work was presented at the XII International Conference 
on Calcium Regulating Hormones, Melbourne, Australia, 14-19 Febru- 
ary 1995, and has been pubhshed in abstract form (Udagawa, N., T. Kat- 
agiri, N. Takahashi, H. Murakami, I. Nakamura, D. Zhang, T. Tamura, 
T.J. Martin, and T. Suda. 1995. Bone 16:92S). 
1Abbreviations used in this paper: 1a,25(OH)2 D3,1a,25-dihydroxyvitamin 
D3;  GAPDH, glyceraldehyde 3-phosphate dehydrogenase; IL-6R., IL- 
11Ik, IL-6 and  IL-11 receptor, respectively; slL-6R, soluble IL-6R; 
OCL, osteoclast-like multinucleated cells; TRAP, tartrate-resistant acid 
phosphatase. 
(1).  Thus the concept that bone-resorbing agents must act 
first on osteoblastic stromal cells  to induce  the generation 
of new osteoclasts has emerged (2-4), although some con- 
troversial reports suggest that osteoblastic stromal cells  are 
not required for osteoclast differentiation (5-7). 
We developed a coculture system of mouse hematopoie- 
tic and primary osteoblastic stromal cells with which to in- 
vestigate osteoclast development in vitro (8).  In these  co- 
cultures, osteoclast-like multinucleated cells (OCLs) formed 
in response to several bone-resorbing factors such as lcx,25- 
(OH)2D3,  parathyroid  hormone,  parathyroid  hormone- 
related  protein,  PGE2,  IL-1,  and  IL-6  (9-11).  OCLs 
formed in these cocultures satisfied  the major criteria of au- 
thentic  osteoclasts,  including  tartrate-resistant  acid  phos- 
phatase  (TRAP)  activity,  calcitonin  receptor  expression, 
and formation of resorption pits  on  dentine  slices  (8,  12, 
13).  When  osteoclast  progenitors  and  osteoblastic  cells 
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OCLs were formed, even in the presence of bone-resorb- 
ing agents. Osteoblastic stromal cells,  therefore, play an im- 
portant  role  in modulating  the  development  of osteoclast 
progenitors  by mechanisms  requiring  cell-cell  interaction 
(14--16).  At  this  time,  it  is  not  clear whether  osteoblastic 
cells  or  osteoclast  progenitors  are  the  primary  target  cells 
for bone-resorbing  agents  in  osteoclast  differentiation.  In 
this  study, we identified which of the  cocultured cells  are 
the target cells for IL-6, which is now recognized as an im- 
portant osteotropic factor. 
IL-6 is a multifunctional cytokine that regulates pleiotro- 
pic functions in many types of cells  (17). There is much ev- 
idence to suggest that IL-6 is an important osteotropic fac- 
tor.  IL-6 is  produced  by osteoblastic  cells  in  response  to 
bone-resorbing  agents  (18,  19)  and  stimulates  osteoclastic 
bone resorption in organ cultures (20). Anti-IL-6 antibody 
inhibits the bone-resorbing activity of OCLs obtained from 
giant cell tumors of bone  (21).  IL-6 causes hypercalcemia 
in vivo  (22,  23)  and has been implicated  in  the  bone loss 
caused by estrogen deficiency.  Ovariectomy in the  mouse 
causes  a  marked  increase  in  ex  vivo  OCL  formation  in 
marrow cultures  (24). Jilka et al.  (25)  have shown that es- 
trogen  replenishment  inhibits  IL-6 production  by  osteo- 
blastic  cells  and  that  anti-IL-6  antibody  prevented  OCL 
development  in  the  estrogen-deplete  state.  Since  IL-6- 
deficient transgenic  mice maintained  their bone mass after 
ovariectomy  (26),  it  is  likely  that  IL-6 is  involved in  the 
differentiation  of osteoclasts  and  osteoclastic  bone  resorp- 
tion in estrogen deficiency.  However,  the  mechanisms by 
which  IL-6 influences  osteoclast formation have not been 
established. 
While  investigating  the  action of IL-6 on OCL forma- 
tion, we found that soluble IL-6 receptors (slL-6R), which 
lack  both  transmembrane  and  cytoplasmic  domains,  can 
also  bind  IL-6  and  mediate  IL-6 signaling  by interacting 
with  the  signal-transducing  receptor  component,  gp130 
(27).  Whereas  mouse  IL-6 alone  did  not  stimulate  OCL 
formation  in  cocultures  of mouse  bone  marrow  cells  and 
osteoblastic  ceils  (11),  the  simultaneous  addition  of mouse 
sIL-6R strikingly  triggered  OCL formation  in  the  cocul- 
tures.  This suggests that cells  in these cultures do not nor- 
mally express IL-6 receptors but express gp130. IL-11, leu- 
kemia  inhibitory  factor,  and  oncostatin  M,  which  share 
gp130 as the  common signal transducer  (28,  29),  similarly 
stimulated OCL formation in the cocultures.  The potency 
of these cytokines to induce OCLs may reflect the number 
of respective receptors in bone marrow and/or osteoblastic 
cells.  It  is  important  to  emphasize  that  none  of  these 
gp130-stimulatory  cytokines  could  induce  OCLs  when 
bone marrow and osteoblastic  cells  were cocultured with- 
out direct contact.  Together,  these  results suggest that the 
gp130  signal  is  involved  in  osteoclast  development,  al- 
though it remains to be clarified which cells  in the  cocul- 
tures primarily require such a signal. 
In this study, we first examine the role of IL-6 in OCL 
formation  in  the  coculture  system,  and  then  demonstrate 
that  dexamethasone  stimulates  expression  of membrane- 
bound IL-6 receptors (IL-6R) on osteoblastic cells,  leading 
to the differentiation of OCLs in response to mouse IL-6 in 
cocultures without a requirement for added mouse slL-6R. 
We  also  show  that  osteoblastic  cells  obtained  from trans- 
genic  mice  constitutively  expressing  membrane-anchored 
human  IL-6R can support  osteoclast differentiation  in  re- 
sponse  to  human  IL-6  in  cocultures  with  normal  spleen 
cells.  This  indicates  that  it  is  osteoblastic  cells  rather  than 
osteoclast progenitors that require  the gp130 signal during 
OCL for,nation in the coculture system. 
Materials and Methods 
Animals and Drugs.  Newborn  ddY  and  6-9-wk-old  male 
ddY  mice  were  obtained  from  Shizuoka  Laboratories  Animal 
Center  (Shizuoka,  Japan).  1ot,25(OH)2D 3 was  purchased  from 
Wako Pure  Chemical Co.  (Osaka, Japan).  Dexamethasone  was 
purchased from Sigma  Chemical Co.  (St. Louis,  MO).  Mouse 
rlL-6 and mouse rslL-6R were prepared  as described  (11,  30). 
Human rlL-6 and human rlL-11 were purchased from R&D Sys- 
tems,  Inc.  (Minneapolis,  MN).  Other  chemicals  and  reagents 
were of analytical grade. 
Construction of the Human IL-6R  Transgene and Preparation of. 
Transgenic Mice.  The IL-6R transgene  was prepared by inserting 
a 1.7-kb fragment of the human IL-6R cDNA (31) spanning the 
entire coding region into a unique XhoI site of the pCAGGS ex- 
pression vector carrying the constitutively active chicken ~-actin 
gene promoter (32). This vector was then digested with Sad and 
HindlII to generate a linear  fragment and microinjected into the 
pronudei of fertilized  BDF1 mouse eggs. Mice were obtained as 
described  (33-35). Newborn transgenic  mice were generated by 
mating animals from human IL-6R-transgenic lines and normal 
C57BL/6 mice,  and their genotypes were  determined by PCR 
analysis of liver DNA from each mouse as described  (35). 
Coculture System and Determination of Osteoclast Characteristics. 
Normal osteoblastic  cells were prepared from the calvaria of 2-d- 
old mice by digestion  with 0.1% collagenase (Wako Pure Chem- 
ical Co.) and 0.2% dispase (Godo Shusei, Tokyo, Japan).  Normal 
bone marrow and spleen cells were obtained from 7-wk-old ddY 
mice as described  (11, 36). To isolate osteoblastic cells from trans- 
genic mice overexpressing human  IL-6R, each  calvarium  front 
2-d-old mice was cut into small pieces and embedded into type I 
collagen  gels according to the manufacturer's instructions  (Cell- 
matrix  Type l-A; Nitta Gelatin  Co., Osaka, Japan).  After culture 
for 3 d, osteoblastic  cells grown from the calvaria were collected 
by treating with  PBS  containing 0.1%  collagenase  (36). Spleen 
cells from transgenic  mice were prepared from the splenic tissues 
of individual  littermates  (36). Osteoblastic  cells were cocultured 
with bone marrow or spleen  cells as described  (11, 36). In short, 
primary osteoblastic cells (104 per well) and nucleated spleen cells 
(5 ￿  10  s per well) or marrow cells (2 ￿  10  s per well) were cocul- 
tured in the wells of a 48-well plate  (Coming Glass Inc., Corn- 
ing,  NY) with 0.4 ml of o~-MEM (GIBCO BRL, Gaithersburg, 
MD)  containing  10%  fetal  bovine  serum  (Cytosystems,  Castle 
Hill,  NSW, Australia) in the presence  of test chemicals.  Cultures 
were incubated in  quadruplicate,  and cells were replenished  on 
day 4  with  fresh  medium.  OCL formation was  evaluated  after 
culturing  for  7  d.  Adherent  cells were  fixed  and  stained  for 
TRAP, and the number of TRAP-positive OCLs was scored as 
described  (11). The expression ofcalcitonin receptors  was also as- 
sessed  by  autoradiography  using  12sI-salmon  calcitonin  as  de- 
scribed  (11). 
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osteoblastic cells  in  flasks  (175  cm2; Nunc  Inc.,  Naperville, IL) 
were cultured with or without 10 -7 M  dexamethasone for vari- 
ous periods after reaching confluence, and total cellular RNA was 
extracted using guanidine thiocyanate-phenol chloroform  (37). 
RNA  was  also  prepared from mouse  spleen and  bone  marrow 
cells, 
Single-stranded cDNA was  synthesized from  2.5  ~g of total 
RNA by incubating for 1 h at 42~  with avian myeloblastosis vi- 
res reverse transcriptase (Promega Corp., Madison, WI) and ran- 
dom hexanucleotides (Promega Corp.). From this reaction mix- 
ture, 2.5  ~l of 25  t~1 was amplified by PCR  to generate mouse 
IL-6R mP~A, IL-11R mtU~A, and mouse glyceraldehyde 3-phos- 
phate  dehydrogenase (GAPDH)  mRNA.  The  reaction mixture 
contained 50 pmol of each primer, 25 mM dATP, dGTP, dCTP, 
and dTTP  (Pharmacia, Uppsala, Sweden), 2  ~1 of 10>( reaction 
buffer, 1 U  ofTaq DNA polymerase (Boehringer Mannheim, In- 
dianapolis, IN), and sterile distilled water, and was overlayed with 
50  wl of paraffin oil. PCR  (IL-GR) was performed for 23 cycles 
at 94~  for 1 rain, at 65~  for 1 rain, and at 72~  for 1 min in a 
DNA  thermal  cycler (model  480;  Perkin  Elmer  Cetus  Instru- 
ments, Norwalk, CT).  Preliminary experiments were performed 
to ensure that the number of PCR cycles were within the expo- 
nential phase of the amplification curve. PCR products were re- 
solved on a 2% wt/vol agarose gel, and the specificity of the reac- 
tion was confirmed by Southern transfer onto nylon membranes 
(Hybond-N; Amersham, Arlington Heights,  IL)  and  hybridiza- 
tion with 32p-labeled internal oligonucleotide probes. 
Oligonucleotides  were  synthesized  on  a  DNA  synthesizer 
(model 381A;  Applied Biosystems, Inc.,  Foster City, CA).  The 
oligonucleotides  for  mouse  IL-6R  were  5'-CCTGTGTGG- 
GGTTCCAGAGGAT-3' (3' primer complementary to nucleo- 
tides 980-1001)  and 5'-CTGCCAGTATTCTCAGCAGCTG-3' 
(5'  primer complementary to  nucleotides 488-519).  The prod- 
ucts were verified by hybridization with the internal oligonucleo- 
tide, 5'-CACAACGAAGCGTTTCACAGCTT-3', by Southern 
hybridization. The oligonucleotides for mouse IL-11R (38) were 
5'-GGAGGCCTCCAGAGGGT-3'  (3'  primer complementary 
to nucleotides 661--677) and 5'-GGGTCCTCCAGGGGTCCAG- 
TATGG-3' (5' primer complementary to nucleotides 133-156). 
The products were verified by Southern hybridization with the 
internal oligonucleotide, 5 '-CTCCTGTACTTGGAGTCCAGG-3'. 
To ensure equal starting quantities of DNA for the experiments, 
and to allow semiquantitation of the PCR products representing 
IL-6R or  IL-11R,  reverse-transcribed RNA  samples were  also 
amplified  using  oligonucleotide  primers  specific  for  GAPDH 
(39). Oligonucleotides for GAPDH were 5'-AACGGATACAT- 
TGGGGGTAG-3' (complementary to nucleotides 701-720) and 
5'-CATGGAGAAGGCTGGGGCTC-3' (complementary to nu- 
cleotides 306-325).  The products were verified by hybridization 
with  the  internal  oligonucleotide, 5'-GCTGTGGGCAAGGT- 
CATCCC-3'. 
Immunoblotting.  After  incubating  osteoblastic  cells  with  or 
without dexamethasone (10 -7 M) for 48 h in flasks (25 cm2; Com- 
ing Glass Inc.), they were stimulated with or without IL-11 (500 
ng/ml)  or IL-6 (1  btg/ml) for 7 rain. The cells were washed in 
situ with ice-cold PBS, lysed in 100 bU oflysis buffer (0.5% NP- 
40/10  mM  Tris-HCl, pH 7.6/150  mM NaCl/5  mM EDTA/2 
mM  Na3Vo4/1  mM  PMSF/5  t*g of aprotinin/ml), then  deter- 
gent-insoluble materials were pelleted by centrifugation (15,000 g 
for 20  min  at  4~  as described (40).  The  solubilized proteins 
were  separated on  a  7.5%  SDS-polyacrylamide gel, then  trans- 
ferred to a membrane (Immobilon-P; Millipore Corp., Bedford, 
MA).  The  proteins  were  immunostained  with  antiphosphoty- 
rosine mAb (PY20)  (Seikagaku Kogyo, Tokyo, Japan)  using an 
enhanced chemiluminescence Western blotting detection system 
(Amersham) according to the manufacturer's recommendations. 
Results 
Effects of Dexamethasone  on OCL Formation Induced by IL-6. 
In the first series of experirnents, we examined TRAP-pos- 
itive OCL formation in cocultures of bone marrow and os- 
teoblastic cells from ddY mice.  IL-11  (10 ng/ml) was used 
as  a  positive  control  to  stimulate  OCL  formation  in  the 
cocultures.  In the absence of dexamethasone,  mouse  IL-6 
(100 ng/ml) failed to induce OCL formation in the cocul- 
tures.  The  simultaneous  addition  of mouse  slL-6R  (200 
ng/ml)  and  mouse  IL-6  (100  ng/ml)  to  the  cocultures 
strikingly triggered OCL  formation  (Fig.  1 A).  In marked 
contrast,  when  10 -v  M  dexamethasone  was  added to  the 
cocultures,  mouse  IL-6  (100  ng/ml)  alone  also stimulated 
OCL formation. In the presence ofdexamethasone, mouse 
IL-6  (10-400  ng/ml)  dose  dependently  stimulated  OCL 
formation  without  the  help  of mouse  slL-6R  (data  not 
shown).  Dexamethasone alone had no effect on OCL for- 
mation. An autoradiographic study using labeled calcitonin 
revealed that TRAP-positive multinucleated and mononu- 
clear cells formed  in  these  cocultures  possessed  calcitonin 
receptors (data not shown). 
Expression of lL-6R and IL-11R mRNA on Osteoblastic Cells 
and Osteoclast Progenitors.  We  investigated  the  expression 
of IL-6R on osteoblastic, spleen, and bone marrow cells by 
Figure  1.  Effects  of mouse IL-6  (rolL-6) and soluble mouse IL-6R 
(smlL-6R) on TRAP-positive OCL formation in cocultured mouse bone 
marrow and osteoblastic cells in the absence (A) or presence (B) of dex- 
amethasone. Mouse  bone  marrow  and primary osteoblastic cells were 
cocultured in the presence or absence of raiL-6 (100 ng/ml),  smlL-6R 
(200 ng/ml),  and 10 -7 M dexamethasone, separately or in combination. 
IL-11  (10  ng/ml)  was  a positive control  to  stimulate TRAP-positive 
OCL  formation.  After  culture  for  7  d,  TRAP-positive  OCLs  were 
counted. Data are expressed as the means +  SEM of quadruplicate cul- 
tures. 
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the osteoclast progenitors,  mouse  spleen  (SP) and  bone  marrow  (BM) 
cells. Osteoblastic cells were incubated  with (+) or without (-)  10 -7 M 
dexamethasone  (Dex) for 12, 24, and 48 h. The spleen and bone marrow 
cells were isolated immediately before use. Total 1LNA was reverse tran- 
scribed and amplified by 23 cycles of PCtL for mouse IL-6tL mB.NA and 
20 cycles for mouse GAPDH mRNA using the specific primers described 
in Materials and Methods. PCtL products were transferred to a nylon mem- 
brane and hybridized with 32p-labeled internal sense oligonucleotides spe- 
cific to the mouse IL-6IL or the GAPDH sequences, respectively. 
reverse transcription  PCIk with mouse  IL-6R-specific oli- 
gonucleotides. Mouse primary osteoblastic stromal cells ex- 
pressed  only  a  low  level of IL-6R.  mRNA.  Treatment  of 
osteoblastic  cells with  10 .7  M  dexamethasone  for  12-48  h 
markedly  increased  IL-61:(  mt(NA  expression  (Fig.  2). 
Fresh mouse spleen and bone marrow cells, however, con- 
stitutively expressed relatively high levels of IL-6R mRNA 
(Fig. 2).  In contrast,  IL-11R mRNA  was constitutively ex- 
pressed  on  osteoblastic  cells irrespective of the presence  or 
absense  of dexamethasone  (Fig. 3).  Fresh mouse spleen and 
bone marrow  cells also expressed IL-11R  rnRNA  (Fig. 3). 
The  results  suggest  that  OCL  formation  in  the  cocultures 
in  response  to  gp130-stimulatory  cytokines  may be  deter- 
mined  by  the  expression  of a  ligand-binding  chain  of the 
receptor  complex in  osteoblastic  cells.  A  sandwich  ELISA 
did not detect mouse  slL-6IL (30)  in  the conditioned  me- 
dium  of cocultures  of bone  marrow  and  osteoblastic  cells, 
either in the presence or absense  of dexamethasone  (detec- 
tion limit,  1.0 ng/ml; data not shown). 
Analysis of Protein  Tyrosine Phosphorylation in  Osteoblasts. 
The signals induced by cytokines that use gp130  as a signal 
transducer  trigger the activation of some tyrosine kinases at 
an  early  step  of the  signal  transduction  pathway  (29,  40). 
To evaluate whether the IL-6 and IL-11 signaling pathways 
Figure 4.  Protein tyrosine phosphorylation  in osteoblastic cells. Osteo- 
blastic cells were incubated with (+) or without (-) 10  -7 M dexametha- 
sone (Dex) for 48 h, then stimulated with or without mouse IL-6 (1 Ixg/ 
ml) or IL-11  (500 ng/ml) for 7 rain.  Antiphosphotyrosine  imnmnoblots 
of NP-40 detergent-soluble  protein  (30  ~g/sample)  were performed  as 
described in Materials and Methods. 
are  initiated  by the  activation  of tyrosine  kinases  in  osteo- 
blastic cells, we examined protein tyrosine phosphorylation 
in  osteoblastic  cells  incubated  with  dexamethasone  fol- 
lowed by IL-6 or IL-11. Fig. 4  shows Western blots against 
an  antiphosphotyrosine  antibody.  Without  dexamethasone 
pretreatment,  IL-6 stimulation did not tyrosine-phosphory- 
late the 130-kD  protein in osteoblastic cells, whereas IL-11 
stimulation  did.  When  osteoblastic  cells  were  first  incu- 
bated with 10 -7 M  dexamethasone  for 48 h, both IL-6 and 
IL-11  tyrosine-phosphorylated  the 130-kD protein  (Fig. 4). 
OCL Formation in Cocultures of Spleen and Osteoblastic Cells 
from Transgenic Mice Overexpressing Human IL-6R.  To  ex- 
amine  whether  OCL  formation  in  our  coculture  system  is 
Figure  3.  Expression  of IL-11tl.  mtLNA on mouse  osteoblastic cells 
and the osteoclast progenitors, mouse spleen (SP) and bone marrow (BM) 
cells. Osteoblastic cells were incubated  with (+) or without (-)  10 -7 M 
dexamethasone  (Dex)  for 12, 24, and 48 h. The spleen and bone marrow 
cells were isolated immediately before use. Total tLNA was reverse tran- 
scribed  and  amplified by 30 cycles of PCIL for mouse IL-11R mR.NA 
and 20 cycles for mouse GAPDH mILNA using the specific primers de- 
scribed in Materials and Methods.  PCR. products  were transferred to ny- 
lon membranes and hybridized with 32p-labeled internal sense oligonucle- 
otides specific to the mouse IL-11R or GAPDH sequences, respectively. 
Figure  5.  TtLAP-posidve  OCL formation  in cocuhures  of spleen  or 
osteoblastic  cells obtained  from transgenic  mice overexpressing  human 
IL-6IL  [hlL-6R(+)] and  their  counterparts  from  normal  ddY  mice 
(Normal), Cells were cocultured  in the presence or absence of human  IL- 
6  (50 ng/ml),  let,25(OH)2D 3 (1,251)3) (10 -8 M) was used as a positive 
control  to  stimulate  TRAP-positive  OCL  formation.  (A)  Cocultured 
spleen cells from transgenic mice overexpressing human  IL-6R and nor- 
mal ddY osteoblastic cells. (B) Cocultured normal ddY spleen and osteo- 
blastic cells from transgenic mice overexpressing human IL-6P,. After cul- 
ture for 7 d, TRAP-positive OCLs were counted.  Data are expressed as 
the means "4- SEM of quadruplicate cultures. 
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Figure 6.  TRAP-positive OCL formation in cocultures of normal ddY 
mouse-derived spleen cells and osteoblastic  cells obtained from transgenic 
mice  overexpressing human IL-6R.  Cocultures were incubated  in  the 
presence or absence of mouse IL-6 (mlL-6) (100  ng/ml), soluble mouse 
IL-6tk (smlL-6R) (200 ng/ml), and human IL-6 (hlL-6) (50 ng/ml), sep- 
arately  or  in  combination.  After  7  d,  TRAP-positive  OCLs  were 
counted. Data are  expressed  as the means +  SEM of quadruplicate cul- 
tures. 
mediated by the gpl30 signal, which is initiated in  osteo- 
blastic cells, cocultures were made using different combina- 
tions  of osteoblastic  cells  and osteoclast progenitors either 
from transgenic mice overexpressing human IL-6R or from 
normal  mice  and  were  stimulated  with  human  IL-6.  In 
cocultured spleen cells containing osteoclast progenitors ob- 
tained from transgenic mice overexpressing human IL-6R 
and osteoblastic cells from normal ddY mice, 10t,25(OH)2D 3 
(10 -8 M)  stimulated OCL formation, whereas human  IL-6 
(50 ng/ml) did not (Fig.  5 A). In contrast, osteoblastic cells 
obtained from transgenic mice overexpressing human [L-6R 
supported OCL formation in response to human IL-6 (50 
ng/ml)  when  cocultured  with  normal spleen  cells  (Fig.  5 
B).  Osteoblastic cells  obtained from normal littermates did 
not exhibit such a capability (data not shown). Mouse IL-6 
(100 ng/rnl)  did not stimulate OCL formation, even in the 
cocultures  of spleen  cells  from normal ddY  mice and  os- 
teoblastic cells from transgenic mice overexpressing human 
IL-6Fk (Fig.  6).  This  is because mouse  IL-6  is  specific  to 
mouse IL-6R, whereas human  IL-6 binds to both mouse 
IL-6R and human IL-6Fk (30).  Incubating these cocultures 
with mouse IL-6 (100 ng/ml) together with mouse slL-6R 
(200 ng/ml) resulted in OCL formation (Fig.  6). 
IL-6 § slL6R 
Osteoblastic  Stromal  Cells 
Dexamethasone  Osteoclasts 
Figure  7.  The mechanism of IL-6-induced osteoclast  formation and 
the role of dexamethasone. 
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Discussion 
We  reported  that  mouse  IL-6  alone  does  not  stimulate 
OCL formation in cocultures of mouse bone marrow and 
osteoblastic  cells  (11).  Mouse  slL-6R  strikingly  triggered 
OCL formation in response to  mouse  IL-6 in  the  cocul- 
tures. IL-11, leukemia inhibitory factor, and oncostatin M, 
all of which use gp130 as a signal transducer, similarly stim- 
ulated  OCL formation in the cocultures without the help 
of their respective soluble receptors (11). Our findings indi- 
cate that the stimulation of gp130 signaling in the cells  in 
cocultures  (osteoclast progenitors and/or osteoblastic stro- 
mal cells)  plays an important  role in  OCL formation and 
that expression of cytokine-specific receptor chains  deter- 
mines  responsiveness  to  gpl30-stimulatory  cytokines,  for 
example, IL-11 and IL-6. 
Both 1L-11  and IL-6 stimulate mouse myeloid and lym- 
phoid  cells  (41).  Not  only  IL-6,  but  also  IL-11  induced 
acute phase proteins in hepatoma cells and isolated hepato- 
cytes (17,  42). A series of studies have shown that the bio- 
logical actions of lL-11 in hematopoietic cells overlap those 
of other gp130-mediated cytokines. IL-11 inhibits lipopro- 
tein lipase activity and preadipocyte differentiation in mouse 
stromal cells (43-45).  In contrast, the activity of IL-6 to in- 
hibit adipogenesis is very low compared with that of IL-11, 
leukemia  inhibitory  factor,  and  oncostatin  M  in  mouse 
preadipocyte cell lines (44,  46). 
IL-6 as such  has no  direct  effect on mouse osteoblastic 
stromal cells  (47,  48).  However, simultaneous addition  of 
slL-6R  and  IL-6  to  osteoblastic  cell  cultures  caused  a 
marked change in cell growth and alkaline phosphatase ac- 
tivity (48).  These findings  suggest that mouse osteoblastic 
stromal cells  do  not  express functional  IL-6R.  Consistent 
with these results,  our study clearly shows that the expres- 
sion of IL-6R mRNA on mouse primary osteoblastic cells 
was not sufficient to mediate an IL-6 effect.  Dexametha- 
sone strikingly upregulated IL-6R mRNA expression and 
tyrosine phosphorylation in response to IL-6 in osteoblastic 
cells.  In  contrast,  IL-11R  mRNA  was  constitutively  ex- 
pressed in mouse primary osteoblastic cells, which was con- 
sistent with the finding that a transcript homologous with 
IL-11R mRNA  is  expressed in  skeletogenic  cells  (chon- 
droblastic and osteoblastic progenitor cells)  (49).  IL-11 in- 
duced  OCL differentiation in  cocultures  of bone marrow 
and osteoblastic cells,  whereas IL-6 failed to do so.  How- 
ever,  in  the  presence  of dexamethasone,  IL-6  stimulated 
OCL formation without the help of mouse slL-6R. These 
results indicate that dexamethasone induces functional IL-6R. 
expression in osteoblastic stromal cells, which confers upon 
them the ability to trigger the differentiation of postmitotic 
osteoclast precursors into osteoclasts (Fig. 7). 
We  established  transgenic  mice  overexpressing human 
IL-6 (34). Although there was massive plasmacytosis in these 
mice overexpressing human IL-6, no abnormality was ap- 
parent in bone.  Likewise, normal bone and bone marrow 
were formed in mice overexpressing human IL-6R (Hirota, 
H., unpublished observation). In cocultures of spleen cells 
from transgenic mice overexpressing human IL-6R and nor- 
mal osteoblastic cells, osteoclasts were not formed in response to human IL-6. In contrast, osteoblastic cells obtained from 
transgenic  mice  overexpressing  human  IL-61L  supported 
osteoclast differentiation  in response to human  IL-6 in co- 
cultures with normal spleen cells. These results strongly in- 
dicate that IL-6-induced  osteoclast differentiation  depends 
on signal transduction mediated by IL-6tk expressed on os- 
teoblastic cells but not on osteoclast progenitors  (Fig. 7). 
Cytokines that share gpl30  as the common signal trans- 
ducer trigger activation  of unknown  tyrosine kinases at an 
early  step  in  their  signal  transduction  pathways  (28,  29). 
The  JAK  family  of  protein  kinases  (JAK1,  JAK2,  and 
TYK2)  and  the  latent  cytoplasmic  transcription  factor 
APRF/STAT3  participate  in  IL-6  signaling  (40,  50,  51). 
Yin et al. (52)  have identified a  130-kD tyrosine-phospho- 
rylated protein induced by IL-11 as JAK2 tyrosine kinase in 
a preadipocyte cell line. Levy et al.  (53)  have reported that 
the  JAK  family  of  tyrosine  kinases  (JAK1,  JAK2,  and 
TYK2)  is  tyrosine-phosphorylated  by  oncostatin  M  in 
mouse primary osteoblastic cells. Lowe et al.  (54) have'also 
reported  that  IL-11  causes  a  modest  elevation  in  JAK2 
phosphorylation  in  mouse  primary  osteoblastic  cells.  Our 
results show that,  like  IL-11,  IL-6 tyrosine-phosphorylates 
a protein with  a molecular mass of 130 kD in osteoblastic 
cells  exposed  to  dexamethasone,  although  further  studies 
are necessary to determine  whether  this  protein  is a JAK- 
related kinase. 
Glucocorticoids  regulate  some  hormone  and  cytokine 
actions in a variety of ceils and tissues.  Insulin-like  growth 
factor I  receptors  in  rat bone  cells  (55),  [32-adrenergic  re- 
ceptors in smooth muscle cells  (56),  and  calcitonin  recep- 
tors in osteoclasts  (57)  are upregulated  by glucocorticoids. 
Snyers et al. (58) have reported that dexamethasone upreg- 
ulated the number of IL-6R on human  epithelial cells and 
hepatoma cells. Like the occurrence  of osteoporotic  disor- 
ders in Cushing's syndrome, prolonged treatment with phar- 
macological doses of glucocorticoids causes secondary osteo- 
porosis (59). This clinical phenomenon is well characterized 
by increased osteoclastic bone resorption and suppression  of 
osteoblastic bone formation. Although there are several re- 
ports discussing the effect of glucocorticoids  on osteoclastic 
bone resorption  (60-62),  the mechanism of the glucocorti- 
cold action  in stimulating  osteoclastogenesis  and  bone  re- 
sorption has not been  elucidated.  This study indicates  that 
dexamethasone  acts  on  osteoblastic  cells  to  induce  osteo- 
clast differentiation in response to IL-6 (Fig. 7).  It is there- 
fore possible that the early increase in bone resorption dur- 
ing  glucocorticoid  therapy  is  mediated  at  least  in  part  by 
the increase in IL-6 sensitivity ofosteoblastic cells. 
Serum levels ofslL-6R progressively increase after ovari- 
ectomy in women, and estrogen prevents this increase (63). 
Such a pathological role of IL-6 has also been recognized in 
patients  with  rheumatoid  arthritis.  Morever,  we  reported 
that synovial fluids from patients with  rheumatoid  arthritis 
contained  both  IL-6  and  slL-6R  at  sufficiently  elevated 
levels to induce  OCL formation in mouse cocultures  (64). 
These findings suggest that the elevated levels of both IL-6 
and slL-6P, form a complex that causes bone destruction in 
these patients. 
In  conclusion,  IL-6-induced  osteoclast  differentiation 
depends  on signal  transduction  mediated  by IL-6R that is 
expressed  on  osteoblastic  cells  but  not  on  osteoclast  pro- 
genitors.  This study will further our understanding  of sig- 
nal transduction  during osteoclast development induced by 
gp130-mediated cytokines. 
We thank Dr. H. Murakami (Pharmaceutical  Research Center, Meiji Seika Kaisha, Kanagawa, Japan) and 
Dr. I. Nakamura (Department of Orthopedic Surgery, School of Medicine, University of Tokyo, Tokyo, Ja- 
pan) for valuable discussions. 
This work was supported by grants-in-aid 06404067  and 06771640  from the Ministry of Science, Education, 
and Culture of Japan, and a Program Grant from the National Health and Medical Research Council of 
Australia. N. Udagawa is C. R. Roper Research Fellow, University of Melbourne. 
Address correspondence to Dr. Tatsuo Suda, Department of Biochemistry, School of Dentistry, Showa Uni- 
versity,  1-5-8 Hatanodai, Shinagawa-ku,  Tokyo 142, Japan. 
Received for publication  14 April  1995 and in revised  form 5July  1995. 
References 
1. Martin, T.J., N.C. Partridge, M. Greaves, D. Atkins, and K.J. 
Ibbotson.  1979.  Prostaglandin  effects  on  bone  and  role  in 
cancer hypercalcemia. In Molecular Endocrinology.  I. Mac- 
Intyre and  M.  Szelke,  editors.  Elsevier  Science  Publishers, 
Amsterdam. pp. 251-264. 
2.  Chambers, T.J.  1980.  The cellular  basis of bone resorption. 
Clin. Orthop. 151:283-293. 
3.  Rodan,  G.A., and T.J. Martin.  1981.  Role of osteoblasts  in 
hormonal  control  of bone  resorption:  a  hypothesis.  Calcif. 
Tissue Int. 33:349-351. 
4.  Martin, T.J., and K.W. Ng. 1994. Mechanisms by which cells 
of the osteoblast lineage control osteoclast formation and ac- 
tivity.J. Cell. Biochem. 56:357-366. 
5. Kurihara, N., T. Suda,  Y. Miura, H. Nakauchi, H. Kodama, 
K. Hiura, Y. Hakeda, and M. Kumegawa. 1989.  Generation 
ofosteoclasts from isolated hemopoietic progenitor cells. Blood. 
74:1295-1302. 
6.  Lee, M.Y., D.R. Eyre, and W.R.A. Osborne. 1991.  Isolation 
1466  Mechanism of IL-6--induced Osteoclast  Formation of a murine osteoclast colony-stimulating factor. Proc. Natl. 
Acad. Sci. USA. 88:8500-8504, 
7.  Sugimoto, T., K. Kanatani,  H. Kaji, T. Yamaguchi, M. Fukase, 
and K. Chihara.  1993.  Second messenger signaling of PTH- 
and  PTHrP-stimulated  osteoclast-like cell  formation  from 
hemopoietic blast cells. Am. J. Physiol. 265:E367-E373. 
8.  Suda, T., N.  Takahashi, and T.J. Martin.  1992.  Modulation 
ofosteoclast differentiation. Endoc. Rev. 13:66-88. 
9.  Takahashi,  N.,  T.  Akatsu,  N.  Udagawa,  T.  Sasaki,  A. 
Yamagnchi, J.M. Moseley, T.J.  Martin, and T. Suda.  1988. 
Osteoblastic cells are involved in osteoclast formation. Endo- 
crinology. 123:2600-2602. 
10. Akatsu,  T.,  N.  Takahashi,  N.  Udagawa,  K.  Imamura,  A. 
Yamaguchi, K. Sato, N. Nagata, and T. Suda. 1991.  Role of 
prostaglandins in  interleukin-l-induced bone  resorption in 
mice in vitro.J. Bone Miner. Res. 6:183-190. 
11. Tamura,  T.,  N.  Udagawa,  N.  Takahashi,  C.  Miyaura,  S. 
Tanaka, Y. Yamada, Y. Koishihara, Y. Ohsugi, K. Kumaki, 
T. Taga, et al.  1993.  Soluble interleukin-6 receptor triggers 
osteoclast formation by interleukin 6.  Proc. Natl.  Acad.  Sci. 
USA. 90:11924-11928. 
12. Hattersley, G., and T.J.  Chambers.  1989.  Calcitonin recep- 
tors as markers for osteoclastic differentiation: correlation be- 
tween generation of bone-resorptive cells and cells that ex- 
press calcitonin receptors in  mouse  bone  marrow  cultures. 
Endocrinology. 125:1606-1612. 
13. Ikegame, M., M.  Kakopoulos, H.  Zhou,  S.  Houssami, T.J. 
Martin, J.M.  Moseley, and D.M.  Findlay. 1995.  Calcitonin 
receptor isoforms in mouse and rat osteoclasts. J. Bone Miner. 
Res. 10:59-65. 
14. Udagawa,  N.,  N.  Takahashi,  T.  Akatsu,  T.  Sasaki,  A. 
Yamagnchi,  H.  Kodama,  T.J.  Martin,  and  T.  Suda.  1989. 
The  bone  marrow-derived stromal  cell lines MC3T3-G2/ 
PA6  and  ST2  support osteoclast-like cell differentiation in 
co-cultures with mouse spleen cells. Endocrinology. 125:1805- 
1813. 
15. Udagawa,  N.,  N.  Takahashi,  T.  Akatsu,  H.  Tanaka,  T. 
Sasaki,  T.  Nishihara,  T.  Koga,  T.J.  Martin,  and  T.  Suda. 
1990.  Origin of osteoclasts: mature monocytes and macro- 
phages are capable of differentiating into osteoclasts under a 
suitable  microenvironment  prepared  by  bone  marrow- 
derived stromal cells.  Proc. Natl.  Acad.  Sci. USA.  87:7260- 
7264. 
16. Chambers,  T.J., J.M.  Owens,  G.  Hattersley,  P.S. Jat,  and 
M.D.  Noble.  1993.  Generation of osteoclast-inductive and 
osteoclastogenic cell lines from  the H-2KbtsA58  transgenic 
mouse. Proc. Natl. Acad. Sci. USA. 90:5578-5582. 
17. Kishimoto, T.,  S.  Akira, and T.  Taga.  1992.  Interleukin 6 
and  its  receptor:  a  paradigm  for  cytokines.  Science (Wash. 
DC). 258:593-597. 
18. Ishimi, Y., C. Miyaura, H. Jin, T. Akatsu, E. Abe, Y. Naka- 
mura, A. Yamaguchi, S. Yoshiki, T. Matsuda, T. Hirano, et 
al. 1990. IL-6 is produced by osteoblasts and induces bone re- 
sorption.J. Immunol.  145:3297-3303. 
19. Littlewood,  A.J., J.  l:(ussell,  G.R..  Harvey,  D.E.  Hughes, 
R.G.G. Russell, and M.  Goweu.  1991.  The modulation of 
the expression of IL-6 and its receptor in human osteoblasts 
in vitro. Endocrinology. 129:1513-1520. 
20.  L6wik, C.W.G.M., G. van der Pluijm, H. Bloys, K. Hoek- 
man,  O.L.M.  Bijvoet,  L.A.  Aarden,  and  S.E.  Papapoulos. 
1989.  Parathyroid hormone  (PTH)  and  PTH-like  protein 
(PLP) stimulate interleukin-6 production by osteogenic cells: 
a possible role ofinterleukin-6 in osteoclastogenesis. Biochem. 
Biophys. Res.  Commun.  162:1546-1552. 
21. Ohsaki, Y., S. Tanahashi, T. Scarcez, A. Demulder, T. Nish- 
ihara, R. Williams, and G.D. Roodman.  1992.  Evidence for 
an autocrine/paracrine role for interleukin-6 in bone resorp- 
tion by giant cells from giant cell tumors of bone. Endocrinol- 
ogy. 131:2229-2234. 
22. Yoneda,  T.,  M.  Nakai, K. Moriyama, L.  Scott,  N.  Ida, T. 
Kunitomo, and G.R.. Mundy.  1993.  Neutralizing antibodies 
to human interleukin 6 reverse hypercalcemia associated with 
a human squamous carcinoma. Cancer Res. 53:737-740. 
23. Black, K., K. Garrett, and G.R. Mundy. 1991. Chinese ham- 
ster ovarian cells transfected with the murine interleukin-6 
gene  cause  hypercalcemia as  well as  cathexia,  leukocytosis 
and thrombocytosis in tumor-bearing nude mice. Endocrinol- 
ogy. 128:2657-2659. 
24. Kalu, D.N. 1990.  Proliferation oftartrate-resistant acid phos- 
phatase-positive multinucleated cells in ovariectomized ani- 
mals. Proc. Soc. Exp. Biol. Med.  195:70-74. 
25. Jilka, R.L., G. Hangoc, G. Girasole, G. Passeri,  D.C. Will- 
iams, J.S. Abrams, B. Boyce, H. Broxmeyer, and S.C. Mano- 
lagas.  1992.  Increased osteoctast development after estrogen 
loss: mediation by interleukin-6. Science (Wash. DC). 257:88- 
91. 
26.  Poli, V., 1~. Balena, E. Fattori, A. Markatos, M. Yamamoto, 
H.  Tanaka,  and G.A. Kodan.  1994.  Interleukin-6 deficient 
mice are protected from bone loss caused by estrogen deple- 
tion. EMBO (Eur. Mol. Biol. Organ.)J.  13:1189-1196. 
27. Taga, T., M. Hibi, Y. Hirata, K. Yamasaki, K. Yasukawa, T. 
Matsuda, T. Hirano, and T. Kishimoto. 1989.  Interleukin-6 
triggers the association of its receptor with a possible signal 
transducer, gp130. Cell. 58:573-581. 
28. Taga,  T.,  and T.  Kishimoto.  1992.  Cytokine receptors and 
signal transduction. FASEB  (Fed. Am.  Soc. Exp.  Biol.)J.  6: 
3387-3396. 
29. Kishimoto, T., T. Taga, and S. Akira. 1994.  Cytokine signal 
transduction. Cell. 76:253-262. 
30.  Saito, T.,  K. Yasukawa, H.  Suzuki, K. Futatsugi, T.  Fuku- 
naga, C. Yokomizo, Y. Koishihara, H. Fukui, Y. Ohsugi, H. 
Yawata, et al.  1991.  Preparation of soluble murine IL-6 re- 
ceptor and anti-murine IL-6 receptor antibodies.  J. Immunol. 
147:168-173. 
31. Yamazaki, K., T. Taga, Y. Hirata, H. Yawata, Y. Kawanishi, 
B. Seed, T. Taniguchi, T. Hirano, and T. Kishimoto. 1988. 
Cloning and expression of the human interleukin-6 (BSF-2/ 
IFN~) receptors. Science (Wash. DC). 241:825-828. 
32. Niwa, H., K.-I. Yamaura, andJ.-l. Miyazaki. 1991. Efficient 
selection for high-expression transfectants with a  novel eu- 
karyotic vector. Gene. 108:193-200. 
33. Yamaura,  K.,  H.  Kikutani,  V.  Folsom,  L.K.  Clayton,  M. 
Kimoto,  S.  Akira,  S.  Kashiwamura,  S.  Tonegawa,  and  T. 
Kishimoto.  1985.  Functional expression of a  microinjected 
Ea~ gene in C57BL/6  transgenic mice. Nature  (Lond.).  316: 
67-69. 
34. Suematsu, S.,  T. Matsuda, K. Aozasa, S. Akira, T.  Nakano, 
and T. Kishimoto. 1989.  IgG1 plasmacytosis in interleukin 6 
transgenic mice. Proc. Natl. Acad. Sci. USA. 86:7547-7551. 
35. Hirota, H., K. Yoshida, T.  Kishimoto, and T.  Taga.  1995. 
Continuous activation ofgpl30, a signal transducing receptor 
component for IL-6-related cytokines, causes myocardial hy- 
pertrophy in mice. Proc. Natl. Acad. Sci. USA. 92:4862-4866. 
36. Takahashi,  N.,  N.  Udagawa,  T.  Akatsu,  H.  Tanaka,  Y. 
Isogai, and T. Suda. 1991.  Deficiency ofosteoclasts in osteo- 
petrotic mice is due to a defect in the local microenvironment 
1467  Udagawa et al. provided by osteoblastic cells. Endocrinology. 128:1792-1796. 
37. Chomczynski, P.,  and N.  Sacchi.  1987.  Single-step method 
of RNA isolation by guanidium thiocyanate-phenol-chloro- 
form extraction. Anal. Biochem. 162:156-159. 
38.  Hilton, D.J., A.A. Hilton, A. Raicevic, S. Rakar, M. Harri- 
son-Smith,  N.M.  Gough,  C.G.  Begley,  D.  Metcalf,  N.A. 
Nichola, and T.A. Willson. 1994. Cloning ofa murine IL-11 
receptor 0~-chain:  requirement  for  gp130  for  high  affinity 
binding and signal transduction. EMBO (Eur. Mol.  Biol.  Or- 
gan.)J.  13:4765-4775. 
39. Tso, J.Y.,  X.H.  Sun,  T.H.  Kao,  K.S.  Reece,  and R.  Wu. 
1985.  Isolation and characterization of rat and human glycer- 
aldehyde-3-phosphate dehydrogenase cDNAs: genomic com- 
plexity and  molecular evolution of the  gene.  Nucleic Acids 
Res. 13:2485-2502. 
40.  Narazaki, M., B.A. Witthuhn, K. Yoshida, O. Silvennoinen, 
K. Yasukawa, J.N. Ihle, T. Kishimoto, and T. Taga. Activa- 
tion ofJAK2 kinase mediated by interleukin 6 signal trans- 
ducer gp130. Proc. Natl. Acad.  Sci. USA. 91:2285-2289. 
41. Paul,  S.R.,  F.  Bennett,  J.A.  Calvetti,  K.  Kelleher,  C.R. 
Wood, R.M. O'Hare, Jr., A.C. Leary, B. Sibley, S.C. Clark, 
D.A. Williams, and Y.-C. Yang. 1990.  Molecular cloning of 
a cDNA encoding interleukin-11: a stromal cell-derived lym- 
phopoietic and hematopoietic cytokine. Proc. Natl. Acad.  Sci. 
USA. 87:7512-7516. 
42. Baumann,  H., and P.  Schendel.  1991.  Interleukin 11  regu- 
lates the hepatic expression of the same plasma protein genes 
as interleukin 6.J. Biol.  Chem.  266:2024-2027. 
43. Kawashima,  I., J.  Ohsumi,  K.  Mita-Honjo,  K.  Shimoda- 
Takano,  H.  Ishikawa,  S.  Sakakibara,  K.  Miyadai,  and  Y. 
Takiguchi.  1991.  Molecular cloning of a  cDNA  encoding 
adipogenesis inhibitory factor and identity with interleukin- 
11. FEBS (Fed. Eur.  Biochem. Soc.) Lett.  283:199-202. 
44. Yin, T., K. Miyazawa, and Y.-C. Yang.  1992.  Characteriza- 
tion  of interleukin-ll  receptor and  protein tyrosine phos- 
phorylation  induced  by  interleukin-11  in  mouse  3T3-L1 
cells.J. Biol.  Chem. 267:8347-8351. 
45. Keller, D.C.,  X.X.  Du,  E.F Srour, R.  Hoffman,  and D.A. 
Williams. 1993. Interleukin-ll inhibits adipogenesis and stim- 
ulates  myelopoiesis in  human  long-term  marrow  cultures. 
Blood. 82:1428-1435. 
46. Gimble, J.M.,  F. Wanker, C.S. Wang,  H. Bass, X. Wu, K. 
Kelly, G.D. Yancopoulos, and M.R. Hill. 1994.  Regulation 
of bone  marrow  stromal  cell  differentiation by  cytokines 
whose receptors share the gp130 protein.J. Cell. Biochem. 54: 
122-133. 
47. Littlewood, A.J., J. Russell, G.R. Harvey, D.E. Hughes Evans, 
R.G.G. Russell, and M.  Gowen.  1991.  Human  osteoblast- 
like  cells  do  not  respond  to  interleukin  6  (IL-6). J.  Bone 
Miner.  Res. 6:141-148. 
48.  Moriyama, K., M. Niewolna, G.R. Mundy, and T. Yoneda. 
1994.  Recombinant  human  soluble  interleukin-6  receptor 
(rhslL-6R)  alters growth and phenotypic expression in hu- 
man osteoblastic osteosarcoma MG-63 through gp130-medi- 
ated mechanism.J. Bone Miner.  Res.  9:$150. (Abstr.) 
49. Neuhaus,  H.,  B.  Bettenhausen,  P.  Bilinski,  D.  Simon- 
Chazottes, J.-L. Guenet, and A. Gossler. 1994.  Etl2, a novel 
putative  type-I  cytokine  receptor  expressed  during  mouse 
embryogenesis at high levels in skin and cells with skeletoge- 
nic potential. Dev. Biol.  166:531-542. 
50. Lutticken, C.,  U.M.  Wegenka, J.  Yuan, J.  Buschmann,  C. 
Schindler, A. Ziemiecki, A.G. Harpur, A.F. Wilks, K. Ya- 
sukawa, T. Taga, et al. 1994. Association of transcription fac- 
tor APRF and protein kinase Jakl with the interleukin-6 sig- 
nal transducer gp130. Science (Wash.  DC). 263:89-92. 
51.  Stahl, N.,  T.G.  Boulton,  T.  Farrugella, N.Y.  Ip,  S.  Davis, 
B.A. Witthuhn, F.W. Quelle, O. Silvennoinen, G. Barbieri, 
$.  Pellegrini, et al.  1994.  Association and activation of Jak- 
Tyk  kinases  by  CNTF-LIF-OSM-IL-61B receptor  compo- 
nents. Science (Wash.  DC). 263:92-95. 
52. Yin,  T.,  K.  Yasukawa,  T.  Taga,  T.  Kishimoto, and Y.-C. 
Yang. 1994. Identification ofa 130-kilodalton tyrosine-phos- 
phorylated protein induced by  interleukin-ll  as JAK2  ty- 
rosine kinase, which associates with gp130 signal transducer. 
Exp. Haematol. 22:467-472. 
53. Levy, J.B.,  R.  Baron,  and M.C.  Horowitz.  1994.  Oncosta- 
tin-M induces signal  transduction by non-receptor tyrosine 
kinases in  primary osteoblasts. 3".  Bone  Miner.  Res.  9:$149. 
(Abstr.) 
54.  Lowe, C., G.A.J. Gillespie, and J.W. Pike. 1994.  Activation 
of the JAK/STAT signal transduction pathway in murine os- 
teoblasts.J. Bone Miner.  Res. 9:$234. (Abstr.) 
55. Bennett,  A.,  T.  Chen,  D.  Feldman,  R.  Hintz,  and  R.G. 
Rosenfeld. 1984.  Characterization of insulin-like growth fac- 
tor receptors on cultured rat bone cells: regulation of receptor 
concentration  by  glucocorticoids. Endocrinology.  115:1577- 
1583. 
56.  Collins, S., M.G. Caron, and R.J. Lefkowitz. 1988.  ~2-adr- 
energic receptors in  hamster smooth muscle  cells  are  tran- 
scriptionaUy regulated by glucocorticoids.J. Biol.  Chem.  263: 
9067-9070. 
57. Wada, S., T. Akatsu, T. Tamura, N. Takahashi, T. Suda, and 
N. Nagata. 1994.  Glucocorticoid regulation of calcitonin re- 
ceptor in mouse osteoclast-like multinucleated cells. J.  Bone 
Miner. Res. 9:1705-1712. 
58.  Snyers, L., L.D. Wit, and J.  Content.  1990.  Glucocorticoid 
up-regulation of high-affinity interleukin 6 receptors on hu- 
man  epithelial cells.  Proc. Natl.  Acad.  Sci. USA.  87:2838- 
2842. 
59. Theodore, J., and J.  Hahn.  1993.  Steroid and drug-induced 
osteopenia. In Primer on  the Metabolic Bone  Diseases  and 
Disorders of Mineral Metabolism. 2nd ed. M.J. Favus, editor. 
Raven Press, New York. pp. 250-255. 
60.  Mundy, G.R., M.E. Rick, R. Turcotte, and M.A. Kowalski. 
1978.  Pathogenesis of hypercalcemia in lymphosarcoma cell 
leukemia: role of an osteoclast activating factor-like substance 
and a mechanism of action for glucocorticoid therapy. Am. J. 
Med.  65:600-606. 
61.  Tobias, J., and T.J. Chambers.  1989.  Glucocorticoids impair 
bone resorptive activity and viability of osteoclasts disaggre- 
gated from neonatal rat long bones. Endocrinology. 125:1290- 
1295. 
62.  Gronowicz, G., M.B. McCarthy, and L.G. Raisz. 1990.  Glu- 
cocorticoids stimulate resorption in fetal rat parietal bones in 
vitro.J. Bone Miner.  Res. 5:1223-1230. 
63.  Girasole, G., M. Pedrazzoni, N. Giuliani, G. Passeri, A. Bac- 
chi, P. Sansoni, and M. Passeri.  1995.  Increased levels of hu- 
man serum soluble interleukin-6 receptors in ovariectomized 
women: evidence of a relationship with parathyroid hormone 
and FSH. Bone.  16:98S.  (Abstr.) 
64. Kotake, S., K. Sato, K.J. Kim, N. Takahashi, N. Udagawa, I. 
Nakamura,  A. Yamaguchi,  T.  Kishimoto, T.  Suda,  and  S. 
Kashiwazaki.  1996.  Interleukin-6 and soluble interleukin 6 
receptors in the synovial fluids from rheumatoid arthritis pa- 
tients are responsible for osteoclast-like cell formation. J. Bone 
Miner. Res. In press. 
1468  Mechanism of IL-6-induced Osteoclast Formation 